PHARMATHEN
Acquired by
BC PARTNERS
PHARMATHEN acquired by BC PARTNERS
Target
PHARMATHEN
Acquirer
BC PARTNERS
Context
BC Partners reached an agreement to acquire a majority stake in Pharmathen, partnering with the company's founders who retain a minority shareholding and remain actively involved in the business. The investment thesis centres on leveraging Pharmathen's strong existing platform to pursue selective bolt-on acquisitions, accelerate new product development, and drive international expansion in the growing complex generics pharmaceutical sector. BC Partners intends to support Pharmathen in its ambition to transition from an established European champion into a global pharmaceutical player.
PHARMATHEN, which reported an EBITDA margin of LOGIN in 2014, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (13.3x).
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Pharmathen is a leading European pharmaceutical and drug delivery technology company founded in 1969, specialising in the development and manufacturing of complex "sustained release" drug delivery technologies. The company is the global leader in complex long-acting injectables (LAI) and has established a long-acting therapeutic technologies (LATT) platform, positioning it at the forefront of one of the most technically demanding and high-barrier segments of the pharmaceutical industry. Pharmathen operates a highly differentiated business model combining best-in-class R&D capabilities with FDA-approved manufacturing facilities, serving a blue-chip customer base across nearly 100 countries worldwide.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with PHARMATHEN
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 07/2021 | PARTNERS GROUP | PHARMATHEN | GREECE | Life Sciences | Partners Group acquired 100% of Pharmathen from BC Partners, which had acquired the company in 2015. During its ownership, BC Partners invested over €250 million in R&D and new FDA-approved production facilities, nearly doubled the employee headcount, and repositioned Pharmathen from a traditional European generics manufacturer into a technology-driven global leader in complex drug delivery. The transaction is expected to support Pharmathen's continued growth, particularly into the US market. BC Partners was advised by Jefferies (financial) and Kirkland & Ellis (legal). |
REFERENCES
Authors: mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).
Press release: view release
Acquirer: bc partners